



Celldex Therapeutics, Inc.
Investor Relations Department
119 Fourth Avenue
Needham, MA 02494-2725
United States

[Visit IR website](#)
[Sign-up for email alerts](#)

NASDAQ: CLDX ¹	
Last Trade:	0.51
Trade Time:	3:37 PM ET Jun 25, 2018
Change:	-0.01 (1.352%)
Day Range	0.50 - 0.58
52-Week Range	0.51 - 3.26
Volume	4,950,031
Market Cap. (\$M)	73.702
Shares Out (M)	143.390


¹ The stock information is provided by eSignal, stock charts are provided by EDGAR Online. Stock information is delayed approximately 20 minutes.

Company Profile

Celldex Therapeutics, Inc. is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. Our pipeline is built from a proprietary portfolio of antibodies and immunomodulators used alone and in strategic combinations to create novel, disease-specific therapies that induce, enhance or suppress the body's immune response.

... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

Jun 2, 2018

[Celldex Presents Promising Data from Phase 1/2 Study of Varilumab and Opdivo® at 2018 ASCO Annual Meeting](#)

Jun 1, 2018

[Celldex Therapeutics to Present at the Jefferies 2018 Global Healthcare Conference](#)

May 16, 2018

[Celldex Announces Presentations at the 2018 American Society of Clinical Oncology \(ASCO\) Annual Meeting](#)

May 10, 2018

[Celldex Provides Corporate Update and Reports First Quarter 2018 Results](#)

Apr 20, 2018

[Data from Multiple Celldex Programs Presented at American Association for Cancer Research \(AACR\) Annual Meeting 2018](#)

Events [\[View all \]](#)

There are no events to display at this time. Please check back later.

Financials [\[View all \]](#)

[First Quarter Financial Results](#)

Mar 7, 2018

[Annual Report \(10-K\)](#)

Apr 30, 2018

[Definitive Proxy Statement](#)

May 10, 2018

[Quarterly Report \(10-Q\)](#)

Nov 7, 2017

[Quarterly Report \(10-Q\)](#)

Aug 8, 2017

[Quarterly Report \(10-Q\)](#)